Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice
avatar for Regina Graul, PhD

Regina Graul, PhD

IronWood Pharmaceuticals
SCD Program Leader Director
Regina Graul is the Director of R&D at Ironwood pharmaceuticals with more than 15 years of industrial experience. She is the founder and leader of the internal innovation group charged with identifying and validating new targets and indication opportunities. Additionally, Regina leads the Global Sickle Cell Disease Development Program including the Phase 2 STRONG-SCD clinical study. As the program leader, she leads a large cross functional group that is responsible for the overall strategy and execution of the clinical development program through approval and beyond. Regina is a drug hunter and is driven to discover and develop medicines that will improve treatment for patients suffering from diseases of high unmet need. Regina has worked in various therapeutic areas such as hematology, diabetes, and cardiovascular disease and has vetted and lead multiple research programs that have transitioned into development. She is a trained medicinal chemist and after her post-doctoral work at MIT, she began her career at Ironwood inventing and synthesizing multiple molecules that made their way into clinical development. She received her Ph.D. in synthetic organic chemistry from Rice University.